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Abstract 32 
Three-dimensional (3D) cell culture is a rapidly emerging field which mimics some of the 33 
physiological conditions of human tissues. In cancer biology, it is considered a useful tool in 34 
predicting in vivo chemotherapy responses compared with conventional two-dimensional cell 35 
culture.  We have developed a novel 3D cell culture model of osteosarcoma comprised of 36 
aggregated proliferative tumour spheroids, which shows regions of tumour heterogeneity 37 
formed by aggregated spheroids of polyclonal tumour cells. Aggregated spheroids show local 38 
necrotic and apoptotic regions, and have sizes suitable for the study of spatial distribution of 39 
metabolites by mass spectrometry imaging (MSI). We have used this model to perform a 40 
proof-of-principle study showing a heterogeneous distribution of endogenous metabolites that 41 
co-localise with the necrotic core and apoptotic regions in this model. Cytotoxic 42 
chemotherapy (Doxorubicin) responses were significantly attenuated in our 3D cell culture 43 
model compared with standard cell culture, as determined by Resazurin assay, despite 44 
sufficient doxorubicin diffusion demonstrated by localisation throughout the 3D constructs. 45 
Finally, changes to the distribution of endogenous metabolites in response to Doxorubicin 46 
were readily detected by MSI. Principle component analysis identified 50 metabolites which 47 
differed most in their abundance between treatment groups, and of these, 10 were identified 48 
by both in-software t test and mixed effects ANOVA. Subsequent independent MSI of 49 
identified species were consistent with principle component analysis findings. This proof-of-50 
principle study shows for the first time that chemotherapy-induced changes in metabolite 51 
abundance and distribution may be determined in 3D cell culture by MSI, highlighting this 52 
method as a potentially useful tool in elucidation of chemotherapy responses as an alternative 53 
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1 Introduction 59 
 60 
The current process of drug discovery and development, based on standard cell culture in 61 
vitro assays followed immediately by in vivo studies has produced many effective drug 62 
candidates, however this workflow has limitations. Cells grown in standard or 2-dimensional 63 
cultures (2D) do not reflect the environment within tumours, which contain heterogeneous 64 
cellular environments, with proliferative, quiescent, apoptotic and necrotic regions resulting 65 
from oxygen and nutrient-deprivation. Within tumours, oxygen and nutrient deprivation is in-66 
part due to chaotic vasculature and/or considerable extracellular matrix deposition, leading to 67 
impaired drug delivery to tumours. In contrast cells in 2D culture receive optimal oxygen, 68 
growth factors, and in the case of therapeutics studies, equal drug concentrations equating to 69 
that in the medium. The study of drug distributions and effects on downstream pathways via 70 
metabolomics approaches have successfully been used to predict anti-tumour cytotoxic 71 
responses by the analysis of extracellular metabolites in cancer patients.
1-2
 These 72 
metabolomic studies have been extended to 3-dimensional (3D) cell culture studies, whereby 73 
the environment recapitulates the drug resistance seen in vivo,
3-4
 and have further shown that 74 
metabolomic profiles may predict the malignant potential of cells grown in 3D cell culture.
5 75 
 76 
Numerous 3D cell culture models for the study of drug responses have been developed, 77 
however many of these are unsuited to spatial localisation studies due to the small size of 78 
resulting cell constructs. Sodium alginate, a naturally occurring polysaccharide extracted 79 
from algae, which following chelation with Ca
2+
, forms cross-links creating a scaffold, and 80 
has been used previously for 3D culture of cancerous cells.
6
 This method has the advantage 81 
of being a clonal grown model dependent on the colony-forming ability of cancer cells, 82 
which is a key characteristic of cancer stem cells or tumour initiating cells.
7
 However, in this 83 
model, spheres develop slowly, and few spheres reach over 400µm diameter, which is 84 
insufficient for spatial investigation of molecular distribution by most MSI modalities.
8
  85 
 86 
Multicellular tumour spheroids (MCTS) are formed through use of ultra-low adherence 87 
techniques, which allows the generation of larger, uniform spheres through aggregation, 88 
rather than proliferation, with the possibility of constructs around 1mm size.
8
 MCTS models 89 
show clear hypoxic cores, apoptotic, quiescent and viable regions representative of tumours, 90 
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and both metabolites and proteins have been successfully imaged within 3D cell cultures by 91 
MALDI-MSI.
9
 Furthermore, MALDI-MSI of metabolite distribution is possible, with species 92 
localised to viable and hypoxic core regions in MCTS generated in low-adherence wells.
10
 93 
MALDI-MSI-based metabolite distribution in pellet cultures of chondrocytes show varying 94 
spatial distributions in hypoxic vs. normoxic regions, further supported by pellet cultures 95 
generated in hypoxic conditions.
11
 MALDI-MSI has also successfully demonstrated spatial 96 
and temporal drug distribution (irinotecan, leucovorin, and its metabolites) in 3D MCTS 97 
cultures,
12
 and irinotecan distributions in patient-derived organoids.
13
 Although patient-98 
derived ‘organoid’ models better represent patient tumours than cell line models and are in 99 
development for sarcoma,
14
 these are only well developed for epithelial cancers. Suitable 100 
osteosarcoma cell line-based 3D models to allow disease-relevant in vitro drug responses, 101 
including MSI studies, are required.  102 
 103 
Since many 3D cell culture models such as MCTS are aggregation models, rather than clonal 104 
proliferation models, these may not fully recapitulate the heterogeneous nature of tumours. 105 
Even within apparently homogeneous established cell lines, heterogeneous populations exist, 106 
and adjacent clones of cells may respond differently to the same cytotoxic stimuli.
15
 To 107 
circumvent these limitations, we have developed an aggregated spheroid model, creating 108 
large constructs of ~1mm diameter from isolated, clonal tumour spheres generated from an 109 
alginate bead culture. This creates a tissue construct that is a) sufficiently large for spatial 110 
distribution studies by MSI, b) contains a necrotic core, apoptotic and viable regions and c) 111 
contains intra-tumoural heterogeneity.  112 
 113 
Doxorubicin was chosen to observe drug distribution and identify the metabolomic and 114 
lipidomic response of the 3D cell culture. Doxorubicin is an anthracycline which interferes 115 
with DNA transcription and replication through the stabilisation of topoisomerase II. 116 
Doxorubicin is one of the most widely used drugs for the treatment of high-grade 117 
osteosarcoma.
16
 In this study, we performed a proof-of-principle study to test whether a 118 
heterogeneous metabolite distribution could be detected by MSI, and to image Doxorubicin-119 
induced changes in metabolite changes in response to cytotoxic chemotherapy in 3D cell 120 
culture.   121 
  122 
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2 Methods and Materials 123 
Cell culture 124 
The SAOS-2 osteosarcoma cell line was obtained from American Type Culture Collection 125 
(ATCC) and cultured in MEMα (Lonza Ltd, Switzerland) containing 10% foetal bovine 126 
serum (FBS) and 10 U/ml penicillin and 10 μg/mL streptomycin (Thermo Scientific, USA). It 127 
was maintained in a humidified atmosphere containing 5% CO2 at 37
o
C.  128 
3D cell culture 129 
Following expansion in a monolayer, cell lines were suspended in 1.2% w/v medium 130 
viscosity alginic acid (Sigma-Aldrich, UK) in 0.15M NaCl at 1x 10
5
 cells/mL. Alginate beads 131 
were formed via dropping the cellular suspension in 1.2% w/v alginate/0.15 M NaCl (Sigma-132 
Aldrich, UK) through a 19-gauge needle into 0.2 M CaCl2 (Sigma-Aldrich, UK). After 133 
incubation at 37
o
C for 12 minutes, alginate beads were washed twice with 0.15 M NaCl and 134 
washed twice in complete media before being placed in the appropriate culture media for 28 135 
days. To release clonal tumour spheres from the alginate matrix, alginate beads were 136 
dissolved in 500 µL dissolving buffer per bead (55 mM sodium citrate (Sigma-Aldrich, UK), 137 
30mM EDTA (Sigma-Aldrich, UK), 0.15 M NaCl) for 10 minutes at 37
o
C with agitation. 138 
Following centrifugation, spheroids were immediately placed in 1% agarose-coated (non-139 
adherent) 96 well plates and cultured for a further 7 days.  140 
 141 
Chemotherapeutic treatment of 2D and 3D cultures 142 
Once confluent, SAOS-2 osteosarcoma cells were trypsinised and seeded into 96-well plates 143 
at 5x10
4 
cells/mL. These were allowed to adhere for 24 hours before treatment. Cells were 144 
treated with 0-12.8 µM Doxorubicin hydrochloride (Sigma-Aldrich, UK), or 0-4 μM for 3D 145 
cell culture studies, for up to 48 hours, with treatment media replaced every 24 hours, for 3 146 
independent cell culture experiments. To assess cell activity/survival during treatment a 147 
Resazurin assay was used. Resazurin (Sigma-Aldrich, UK) stock was made at 3mg/mL in 148 
αMEM media. Resazurin diluted in complete media (200 µL of 0.3 mg/mL) was added to 149 
each well and incubated for 1.5 hours (2D culture) or 3 hours (3D culture) at 37
o
C, wrapped 150 
in foil to protect from light exposure. The fluorescence was recorded using a 530 nm 151 
excitation/590 nm emission filter set using a Clariostar microplate reader (BMG Labtech Ltd, 152 
UK). After reading the plates the cultures were washed twice with culture medium and 153 
cultured further until the last remaining time point. Additionally, doxorubicin controls were 154 
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tested in order to confirm the absence of fluorescent interference with the assay. The 155 
Resazurin fluorescence values were shown to deviate from the normal distribution by the 156 
Shapiro-Wilk test of normality. Therefore, the Kruskal-Wallis test was used to determine if 157 
there was a significant difference between Doxorubicin treatments. The Dwass-Steel-158 
Chritchlow-Fligner post-hoc test was performed for all pairwise comparisons when a 159 
significant difference was observed between treatment groups. When a decrease in cell 160 
survival at higher doses was observed, a non-linear regression of (variable) on log10 dose was 161 
fit with four parameters in GraphPad Prism (v7) (GraphPad Software, USA).  162 
 163 
Fluorescent imaging of spheroid aggregates   164 
To visualise drug distribution in spheroid aggregates, cells were treated with 1 M 165 
Doxorubicin for 6 hours then stained for 25 mins with Hoechst 33342 (10 µg/mL). The 166 
fluorescence was visualised on an Olympus IX81 microscope with an Olympus XM10 167 
camera using Texas Red and DAPI channels respectively and analysed using Olympus 168 
Cell^F software (Olympus, Germany). Apoptosis was visualised using NucView 488 169 
Caspase-3 fluorogenic substrate (Biotium, Cambridge Research, UK) as per manufacturers’ 170 
instructions, then counterstained with Hoechst 33342 as above. Necrotic regions were 171 
identified by staining simultaneously with Propidium Iodide and Hoechst 33342 staining 172 
(both 10 µg/mL). 173 
 174 
MALDI-MSI and detection of Doxorubicin in 3D cell culture 175 
A doxorubicin standard-spiked cell plug array was made to aid detection of doxorubicin 176 
inside a spheroid using MALDI-MSI to mimic the signal suppression effects in the samples. 177 
A gelatin block was made by pouring 20% w/v gelatin (Sigma-Aldrich, UK) into ice cube 178 
moulds, setting the moulds (4
o
C) for 4 hours, and transferring to -80
o
C for storage. The block 179 
was transferred from -80
o
C to a -30
o
C cryostat and the top cut down to produce an even 180 
surface. Using a pillar drill, nine 2.5x10mm holes were then drilled into the frozen block 181 
which was mounted in a cryostat set to -30
o
C. SAOS-2 cells were trypsinised, counted, 182 
centrifuged and the supernatant removed.  A range of doxorubicin concentrations (0, 0.031, 183 
0.063, 0.125, 0.25, 0.5, 1, 2, 4 µM) were produced by mixing pelleted cells 2:1 with 184 
doxorubicin diluted in culture medium and placing the mixture in each cell plug hole, filling 185 
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an approximate volume of 49 L, and stored in a sealed container in -80
o
C prior to MALDI-186 
MSI.  187 
 188 
Spheroid aggregates treated with 0, 0.16, 0.8, and 4 µM doxorubicin were harvested at 0 and 189 
48 hours and embedded in 5% w/v gelatin + 2.5% carboxymethylcellulose (CMC) (Sigma-190 
Aldrich, UK) inside a silicone mould, immediately frozen using liquid nitrogen and stored in 191 
air-tight containers. Sample sections were cut using the Leica 1850 UV cryostat (Leica 192 
Biosystems, UK), set to -30ºC, at 10 μm thickness, thaw mounted on a positively charged X-193 
tra® adhesive slide (Leica Biosystems, UK) or on an Indium-Tin oxide (ITO)-coated slide 194 
(Visiontek Systems Ltd, UK), dependant on the analysis. All sample sections were taken 195 
straight after cryosectioning or from -80
o
C storage and immediately placed in a vacuum 196 
desiccator for ~15 minutes prior to matrix application. Negative mode imaging was 197 
performed with NEDC (Sigma-Aldrich, UK) (7 mg/mL, 50% MeOH) prepared as a matrix 198 
solution. The matrix was applied to the sample section using the SunCollect™ (Sunchrom, 199 
Germany) automated sprayer. Fifteen layers of matrix were applied, at 4 μL/min for the first 200 
layer and 3.5 μL/min for the remaining layers (speed x: low 7, speed y: medium 1, Z position: 201 
35).  202 
 203 
Imaging of the Doxorubicin spiked plug array and doxorubicin-treated spheroid aggregates 204 
was initially performed in negative mode using an Autoflex III, as it was equipped with a 205 
smartbeam laser which proved better for doxorubicin detection and was able to detect small 206 
molecules at lower spatial resolution settings. Negative ion mass spectra were acquired at a 207 
pixel size of 30 μm from m/z 50 – m/z 1000 in reflectron mode. The laser was focused to 208 
around 30 μm diameter. Four hundred laser shots were acquired for each spectrum. Data 209 
acquisition was performed using FlexControl (Bruker Daltonics, Germany), and 210 
visualizations were obtained from FlexImaging 4.0 (Bruker Daltonics, Germany). 211 
 212 
MALDI-MSI of Doxorubicin-induced changes to endogenous metabolites in 3D cell 213 
culture 214 
Treated spheroid aggregates (0, 0.8, 4µM) were sectioned as before at 10µm thickness, 215 
ensuring a section from the middle part of the spheroid aggregate was sampled. Three 216 
independent culture experiments were performed, and from each culture, three aggregated 217 
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spheroids were used, and three sections taken from each aggregated spheroid resulted in a 218 
total of 81 sections for MSI. The NEDC matrix deposition protocol used was as above. 219 
 220 
Imaging of metabolite changes in response to Doxorubicin in spheroid aggregates was 221 
executed using a Synapt G2 (Waters, UK) in sensitivity mode as this instrument was capable 222 
of sufficient mass resolution and high enough throughput for the large sample comparison. 223 
Images of 60μm pixel size were acquired. Data was acquired over an m/z range of 50–1,000 224 
in negative mode analysis. For positive mode imaging of doxorubicin inside a spheroid 225 
aggregate, images of 60µm were acquired at m/z 100-1200. The ion mobility function was 226 
used to improve separation of peaks. Data acquisition and analysis was performed using 227 
MassLynx v4.1 (Waters, UK) and High Definition Imaging (HDI) Software (Waters, UK). 228 
Tandem MS fragmentation was performed using an isolation window of 0.3 Da. 229 
 230 
Regions of interest (ROIs) containing whole spheroid aggregates were selected in Waters 231 
HDI 1.4 imaging software and exported as average spectra into MassLynx software. They 232 
were then centroided and exported as .txt files and imported into Marker View software 1.2 233 
(Applied Biosystems/MDS Sciex, Canada). An exclusion list to remove NEDC peaks was 234 
applied to the datasets, to remove the influences of the matrix signals when observing 235 
relationships of the treatment groups between spectra. The data were restricted to 5000 peaks 236 
and 0.1 minimum intensity and autoscaled. Principal Component Analysis-Discriminant 237 
Analysis (PCA-DA) was used to demonstrate that the spectral data could be used to visually 238 
discriminate between doses, and performed by informing the MarkerView software which 239 
samples belonged to each treatment group. The software then selected the two components 240 
that explained the most variance in normalised signal intensity over the peaks between 241 
groups. 242 
 243 
Initially, a pragmatic approach was taken to analysing the data, aimed at balancing statistical 244 
rigour against time requirements for such high dimensional data with the software being used. 245 
Reduced Synapt data generated by the PCA-DA was initially put through a screening by t test 246 
comparison of each treatment group against each other. Potential effects of batch, culture and 247 
slice were ignored. The 50 peaks with lowest P-values for any comparison were then 248 
analysed further. The normalised signal intensities significantly deviated from the normal 249 
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distribution by Shapiro-Wilk tests. Therefore, Kruskal-Wallis tests were applied to each ionic 250 
species to determine if there was a significant effect of dose. This analysis was combined 251 
with Dwass-Steel-Chritchlow-Fligner post-hoc test when a significant difference was seen 252 
between treatment groups. Statistical analysis was performed using StatsDirect software 253 
(StatsDirectLtd, UK). 254 
 255 
The inclusion of different batches, cultures and slices enables the variation due to these 256 
factors to be estimated and accounted for in statistical modelling, which increases the power 257 
to detect any dose effects. The data were exported from MarkerView R (v 3.4.1).
17
 R is 258 
programmable software that enables a statistical test to be automated for very large numbers 259 
of variables.  A linear mixed effect model was fit by restricted maximum likelihood for the 260 
normalised signal intensity of each peak using the function lme in package nlme (v 3.1-261 
131)
18
. Batch and culture nested within batch were fitted as random effects and dose as a 262 
fixed effect 
18
. An effect of dose was tested with an F test by applying the anova function to 263 
the fitted model object. The significance threshold was set to P=1x10
-5
, which is a Bonferroni 264 
correction of P=0.05. Where a significant effect of dose was found, the model was re-run 265 
with the ordering of the levels of dose changed, to obtain P values from t tests of each 266 
pairwise comparison. The residuals from the model were also plotted against the fitted values 267 
to check they met the assumptions of a parametric analysis. 268 
The significantly differing peaks discovered using either statistical approach were given 269 
putative assignments based on a database search in the Human Metabolome, Metlin or 270 
LipidMaps search databases. The error allowance used was 30ppm for small molecules and 271 
0.01 Da for lipid identifications which was acceptable for the data acquired. Following the 272 
database search biological relevance was investigated within the possible identities within 273 
current literature. 274 
 275 
Confirmation of Doxorubicin-induced metabolite changes by Fourier-Transform Ion 276 
Cyclotron Resonance (FT-ICR) MSI  277 
To confirm the findings from the PCA study MALDI-FTICR-MSI of 0, 0.8 and 4µM 278 
doxorubicin-treated spheroid aggregates was performed on a 9.4T SolariX XR mass 279 
spectrometer (Bruker Daltonics, Germany) in negative-ion mode, using 200 laser shots per 280 
spot and 75 μm pixel size. Data was acquired in a m/z range from 50 to 1000 Da. For positive 281 
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mode imaging of doxorubicin inside a spheroid aggregate, 220 laser shots were used per spot 282 
at a 75µm pixel size. Data was acquired at m/z 100-1200. Data acquisition was performed 283 
using ftmsControl (Bruker Daltonics, Germany), and visualizations were obtained from 284 
flexImaging4.0 (Bruker Daltonics, Germany). As this instrument has a higher mass resolving 285 
power, both doxorubicin and the endogenous small molecules were clearer, however the 286 
method was only used to confirm due to large data sizes and analysis time requirements. The 287 
previously determined putative identifications were confirmed with the FTICR analysis 288 
within 3 ppm. 289 
 290 
  291 
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3 Results and discussion 292 
Development of the SAOS-2 aggregated spheroid model 293 
The SAOS-2 spheroid aggregate model was developed to allow sufficient spatial resolution 294 
of metabolites by MSI. Initial growth of SAOS-2 in alginate resulted in colonies typically 295 
200 µM diameter, which may not provide sufficient information in low spatial resolution 296 
imaging experiments. To circumvent this problem, whilst keeping the presence of clonal 297 
heterogeneity, the alginate matrix was dissolved to release clonal tumour spheroids, which 298 
were subsequently aggregated in low-adhesion agarose-coated wells (Fig 1a).  This process 299 
resulted in constructs of up to 1 mm. Staining of aggregated spheroids with Hoechst 33342, 300 
to localise all cells (blue), and propidium iodide, to localise regions containing necrotic cells 301 
(red) revealed heterogeneity across the tissue construct, with a clear viable rim containing no 302 
necrotic cells (Fig 1b). Caspase-3 is one of the executioner caspases at the end of the 303 
apoptotic cascade, and active caspase-3 is characteristic of apoptotic cell death and is present 304 
in regions of hypoxia in 3D cell cultures.
19
 Staining for Caspase-3 activity using the 305 
NucView 488 fluorogenic Caspase-3 substrate revealed heterogeneous regions of apoptosis 306 
localised to the centre of the construct, whilst the viable rim remained devoid of active 307 
caspase-3. These results highlight the heterogeneous nature of aggregated spheroids, which 308 
contrasts with more uniform constructs generated from hanging-drop or aggregation of cell 309 
suspensions in low-adhesion plates. 310 
 311 
Spatial distribution of endogenous metabolites within aggregated spheroids 312 
MALDI-MSI of tumour spheroids revealed regional variations within the aggregated 313 
spheroids (Fig 2). Phosphoric acid (m/z 78.9493) was used to localise the aggregated spheroid 314 
construct. Detection of peaks with considerable variation in spatial distribution within the 315 
spheroid is evident, with  m/z 426.0657 showing focal regions of detection, and m/z 281.2809 316 
absent in the centre, and also at the periphery whereas localisation of m/z 403.1034 can be 317 
seen to localise within the central necrotic core region.  Both m/z 158.9409 and m/z 606.0975 318 
are largely absent from the viable rim region, with the latter showing evidence of 319 
delocalisation beyond the cellular construct, along with phosphoric acid.  320 
 321 
SAOS-2 cells respond to doxorubicin, but not in 3D cell culture 322 
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Treatment of SAOS-2 cells with doxorubicin displayed a dose-dependent and time-dependent 323 
decrease in cell activity in 2D cell culture. Cell activity was reduced at 36 hours treatment 324 
compared to 12 hrs (p< 0.0001) with an IC50 of 1.09 µM after 36 hours (Fig 3a). In contrast, 325 
treatment of 3D aggregated spheroids resulted in no significant reduction of cell viability at 326 
doses up to 4 µM after 48 hours (Fig 3b).  Impaired response to Doxorubicin in 3D cell 327 
culture is not unexpected, and hypoxia-induced resistance to doxorubicin has been reported in 328 
similar models.
20-21
 It is well known that the central regions of MCTS are acutely hypoxic, 329 
resulting in apoptosis and necrosis,
22
 which is consistent with observations seen in this 330 
model, and therefore likely accounting for observed lack of cytotoxic effects in this study.  331 
 332 
To confirm Doxorubicin penetration into the 3D aggregated spheroid constructs, Doxorubicin 333 
distribution was determined by fluorescence microscopy. Since Doxorubicin fluoresces, drug 334 
distribution can easily be seen throughout the aggregated spheroid (red), as compared to 335 
Hoechst 33342 counterstain, which enters all cells (blue) (Fig 3c). After just 6 hours, 1 µM 336 
doxorubicin can clearly be seen staining cells within the spheroid aggregate, whereas post-337 
staining with Hoechst 33342 shows only staining of the outer layer of cells, consistent with 338 
previous observations of Doxorubicin uptake in MCTS models.
23
  339 
 340 
Cell plug arrays were made to aid detection of doxorubicin inside the spheroid aggregates. 341 
This was made by mixing SAOS-2 cells with doxorubicin standard and spiking these cells 342 
into a gelatin block. These could then be sectioned alongside the sample of interest and used 343 
as an internal standard array to demonstrate qualitative changes to doxorubicin within the 344 
sample (Fig 3). 345 
 346 
Initial detection of Doxorubicin within the cell plug arrays was unsuccessful in positive mode 347 
by Q-TOF MS due to a close, interfering lipid peak (Fig 3d). The close interference within 348 
the spheroid aggregates was not significant at higher doxorubicin concentrations but once at a 349 
biologically relevant level, it was substantial. To achieve detection, alternative instrument 350 
types (FT-ICR) and negative mode were used enable visualisations. Putative doxorubicin 351 
could be observed in negative mode showing a promising increase in signal concurrent with 352 
an increase in doxorubicin signal intensity (Fig 3e).   353 
354 
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Detection of endogenous metabolite changes in response to doxorubicin by MSI 355 
In order to define the metabolomic and lipidomic spheroid aggregate response to 356 
Doxorubicin, 48-hour Doxorubicin-treated, and untreated spheroid aggregate sections were 357 
imaged in negative mode. The whole spheroid region was selected, and average spectra were 358 
extracted for comparison between groups. Comparison was performed using PCA-DA, which 359 
takes into account the group the sample belongs to and finds the principle components which 360 
separate these groups. The control and treatment groups were separated, and several species 361 
were separated out in the loading plot, in particular the 4µM treatment group (Fig 4). 362 
 363 
Linear mixed effects analysis 364 
The approach of using a combination of t tests within the MarkerView software to identify 50 365 
peaks for follow-up testing by a Kruskal-Wallis test, found a significant effect of dose on the 366 
normalised signal intensity of 42 species. Some species were discarded as they were 367 
determined to be likely isotopes of other species. Linear mixed effects modelling, which 368 
accounts for variation due to batch and culture effects, found 24 species where the normalised 369 
signal intensity was significantly altered by dose. Of these, 18 were considered to be unique 370 
species (Table 1). Fitting linear mixed models also allowed the random variation in 371 
normalised signal intensity due to effects of batch and culture nested within batch, to be 372 
estimated. In several cases, one of these variances was negligible, and they were always 373 
smaller than the variation amongst slices. Theoretical accurate masses, measured masses and 374 
mass errors in ppm for the putative assignments are shown in Table 2. The assigned species 375 
were also confirmed within the FTICR imaging data.  Ten ionic species (highlighted in Table 376 
1) were detected as significant by both methods, which may be indicative of the strong 377 
significance of these ionic species in drug response. Results for 6 of these species based on 378 
intensities of the whole spheroid area are shown in fig 5. S-nitrosoglutathione (m/z 335.0617) 379 
(15 ppm) is known to modulate doxorubicin responses in breast cancer cells, whereby N-380 
nitrosoglutathione suppressed doxorubicin activity.
24
 N-nitrosylation, for which N-381 
nitrosoglutathione is a mediator, is a key step in regulating DNA repair,
25
 and observed 382 
changes likely reflect a DNA damage response. This molecule has been also been shown to 383 
induce increased expression of stress response genes and proteins.
26
   384 
Putative identification of m/z 378.0869 (28ppm) as S-Lactoylglutathione, which was 385 
significantly increased in response to Doxorubicin, is of potential interest to the study of 386 
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osteosarcoma drug resistance. S-Lactoylglutathione is a known product of the Glyoxalase I 387 
(GLO1) enzyme, and is converted to D-lactate regenerating glutathione (Gillespie, 1978)
27
. A 388 
highly significant increase in ionic species m/z 396.0996 was also found. This was putatively 389 
identified as S-Adenosyl-4-methylthio-2-oxobutanoate (3ppm) a factor of the modified 390 
methionine salvage pathway from 5’-methylthioadenosine (MTA) which could be of interest 391 
in cancer as a regulator of apoptosis and proliferation.
28
 The lipids m/z 714.5375, putatively 392 
identified as PE(O-35:2) (0.0068Da); m/z 758.4969, identified as PS(34:2) (0.0009Da); m/z 393 
765.5488, identified as PA(41:4) (0.0048Da); m/z 791.5778, and identified as PG(37:0) 394 
(0.0030Da) are not directly associated with any known osteosarcoma pathways or 395 
doxorubicin responses. However, m/z 765.5488 showed a striking decrease and may be 396 
worthy of investigating as a possible marker of drug response. 397 
  398 
MALDI-MSI (FT-ICR-MS) performed in negative mode aimed to validate changes in 399 
endogenous metabolites post-Doxorubicin treatment. Metabolomic species were originally 400 
acquired using the Synapt G2 and modelled by PCA-DA. Selected ionic species either 401 
identified as most highly significantly altered by Doxorubicin treatment, or species with 402 
putative identifications with potential relevance to cytotoxic drug responses. MSI is shown in 403 
Fig 6, and m/z 355.0617 is shown for comparison as it localised to the entire spheroid 404 
aggregate across all treatments. Highly consistent with PCA-DA findings (Fig 5), m/z 405 
335.0617, putatively identified as S-nitrosoglutathione showed clear increase, as did m/z 406 
378.0869 and m/z 396.0996 putatively identified as S-Lactoylglutathione and S-Adenosyl-4-407 
methylthio-2-oxobutanoate respectively. Doxorubicin (m/z 542.1668) was identified within 408 
the same imaging experiment in negative mode, which increased in a dose-dependent manner 409 
with treatment, however was only readily detected in the centre of the spheroid where 410 
propidium iodide staining was typically observed. This may reflect an ability for Doxorubicin 411 
to ionise in intact vs. fragmented chromatin of necrotic and apoptotic cells. Ion species m/z 412 
714.5375, 765.5488 and 791.5778 were all shown to be decreased by PCA-DA analysis, and 413 
subsequent FT-ICR MSI showed presence of all three putative lipids but with signals 414 
localised to the centre of the spheroid aggregates. Overall, these data show consistency with 415 
PCA-DA analysis of data obtained using Q-TOF and subsequent FT-ICR MSI imaging. 416 
 417 
Concluding comments  418 
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In this study, we have developed a novel 3D cell culture model for osteosarcoma with cell 419 
constructs of sufficient size for spatial distribution of endogenous metabolites, and the ability 420 
to visualise heterogeneous metabolite distribution within the 3D constructs. We have 421 
demonstrated that within these constructs, we can visualise Doxorubicin, and despite the 422 
apparent lack of cytotoxic activity of Doxorubicin in 3D cell constructs vs. 2D cell culture, 423 
metabolomic changes can be imaged and identified using PCA-DA. As further validation of 424 
the species identified by PCA-DA analysis of Doxorubicin-treated spheroid aggregates, 425 
spatial distribution of changes of some of the most highly significantly altered metabolites 426 
followed similar patterns when independently analysed by FT-ICR. Some of the most highly 427 
significantly up-regulated species were putatively identified as metabolites of the glutathione 428 
system, and agents that modulate the glutathione system are known to modulate Doxorubicin 429 
activity.
29
 In conclusion, MSI of drug-treated 3D cell cultures may identify biologically 430 
relevant metabolite changes highlighting this workflow as a potentially useful tool in in vitro 431 
drug discovery studies.    432 
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P value Putative identification 
180.4920 4.57x10-6  
245.0544* 1.68x10-7  
253.2270 9.89x10-6  
331.0550* 3.48x10-11  
335.0617* <1.00x10-12 S-nitrosoglutathione 
347.0637* 1.14x10-7  
364.0735 1.49x10-9 2-S-glutathionyl acetate 
378.0869* 2.62x10-11 S-lactoylglutathione 
396.0996* <1.00x10-12 S-Adenosyl-4-methylthio-2-oxobutanoate 
404.0321 1.61x10-7  
414.1022* <1.00x10-12  
464.0080 1.29x10-6  
565.9493 1.05x10-6  
583.9583 5.98x10-6  
589.9554* 1.92x10-7  
714.5375 9.77x10-8 PE (O-35:2) 
765.5488* 1.25x10-10 PA (41:4) 
791.5778* 3.10x10-7 PG (37:0) 
 561 
Table 1: Ionic species with a significant effect of dose on normalised signal intensity as tested 562 
by a mixed effects model. The significance threshold was set to P<1x10-5. * indicates species 563 
that were also identified by the combination of t test and Kruskal-Wallis test.  564 
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335.0617 335.0667 15 S-nitrosoglutathione 
364.0735 364.0820 23 2-S-glutathionyl acetate 
378.0869 378.0977 28 S-lactoylglutathione 
396.0996 396.0983 3 S-Adenosyl-4-methylthio-2-oxobutanoate 
714.5375 714.5443 10 PE (O-35:2) 
765.5488 765.5440 6 PA (41:4) 
791.5778 791.5808 4 PG (37:0) 
858.8311 858.8284 3 1-O-behenoyl-Cer(d34:1) 
 565 
Table 2: Theoretical accurate masses, measured masses and mass errors in ppm for the 566 
putative assignments.  567 
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Figure 1: Generation of aggregated spheroid model. a) Cells are suspended in alginate and 572 
clonal proliferative colonies form. Hoechst 33342 identified all cells and Propidium Iodide 573 
identifies regions containing dead cells. b) After alginate dissolution, spheroids are 574 
aggregated in a low-adhesion well. Hoechst 33342 and Propidium iodide staining highlights 575 
a viable rim with necrotic or dead cells present within the construct, co-localised with 576 
caspase-3 activity confirming presence of apoptotic cells within the core. Scale bar=500 µm. 577 
 578 
  579 
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Figure 2: Detection and localisation of endogenous metabolites aggregated spheroid model 586 
by MSI using Bruker Autoflex III. Haematoxylin and Eosin staining shows the outline of the 587 
aggregated spheroid (scale bar = 500 µM). Phosphoric acid (m/z 78.9493) is ubiquitously 588 
present and outlines the aggregated spheroid by MSI. Overlay of phosphoric acid and 589 
endogenous metabolites shows heterogeneity of detection within the aggregated spheroid.  590 
 591 
  592 
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 593 
Figure 3: Effects of Doxorubicin on SAOS-2 cells. a) SAOS-2 cells responded to doxorubicin 594 
treatment in 2D cell culture, as determined by Resazurin assay. b) SAOS-2 did not show 595 
significant reduction in activity after treatment with Doxorubicin at doses in excess of the 596 
IC50 value determined from the 2D culture. c) Fluorescence microscopy of Hoechst 33342 597 
staining (blue), and Doxorubicin (red) localisation throughout aggregated spheroid, 598 
confirming drug uptake into the aggregated spheroid. Scale bar = 500 µM. d and e) 599 
Detection of Doxorubicin in positive mode m/z 544.1827 by FT-ICS-MS (e), whereas this was 600 
not visible by Q-TOF (d) due to a close interfering peak. f) Detection of doxorubicin in 601 
negative mode in the cell-spiked array plug vs. ATP/APD for cellular co-localisation. 602 
Presence of Doxorubicin in a 4µm-treated spheroid aggregate is shown.   603 
   
 
24 
   
 
 604 
Figure 4: a) PCA-DA loading plots showing clear separation by dose and b) the weighting 605 
chart of all ionic peaks, with peaks that make a large contribution to the principle 606 
components being found in the periphery of the main cluster.  607 
 608 
 609 
  610 
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Figure 5: Normalised signal intensity of six ionic peaks at 0, 0.8 and 4 µM Doxorubicin 614 
treatments. Data is from three independent batches, with three sections analysed for each 615 
experiment. Significant differences between pairs of doses from t tests within a linear mixed 616 
model are indicated. Fitted values for each dose from the linear mixed model are shown as 617 
horizontal lines across the data. 618 
 619 
  620 
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Figure 6: Negative mode FT-ICR MSI of selected targets altered by Doxorubin and initially 623 
identified by PCA-DA. Treatment groups are 4 µM, 0.8 µM and control. m/z 355.0617 624 
identified the whole spheroid aggregate, and m/z 542.1668 is Doxorubicin, which shows 625 
predominant localisation in the centre of the spheroid. m/z 335.0617, m/z 378.0869 and m/z 626 
396.0996 show striking increased in response to Doxorubicin, consistent with PDA-DA 627 
analysis. The remaining species are putatively identified as lipids and show a similar spatial 628 
distribution. 629 
 630 
 631 
